Table 1 Baseline characteristics of participants
Participants | Non-participants | P-value | |
|---|---|---|---|
Gender, No. (%) men | 45 (63) | 29 (44.6) | 0.04 |
Age, mean (SD, range) years | 63 (11.5, 24–86) | 65 (11.7, 26–80) | 0.29 |
BMI, mean (SD) kg/m2 | 25.5 (4.5) | 26.2 (5.6) | 0.43 |
Socioeconomic status, mean (SD) score | 0.44 (1.08) | 0.23 (1.00) | 0.24 |
EORTC-QLQ-C30 physical function, mean (SD) score | 78 (21.7) | ||
ECOG/WHO performance score (PS), No. (%) | 0.24 | ||
0 | 25 (35) | 23 (35) | |
1 | 25 (35) | 29 (45) | |
2 | 22 (31) | 13 (20) | |
Tumor type, No. (%) | 0.73 | ||
Colorectal | 16 (22) | 12 (19) | |
Melanoma | 13 (18) | 21 (32) | |
Breast cancer | 13 (18) | 8 (12) | |
Prostate cancer | 6 (8) | 5 (8) | |
Gastric cancer | 4 (6) | 0 (0) | |
Pancreatic cancer | 4 (6) | 0 (0) | |
Other | 15 (21) | 19 (29) | |
Current active treatment type, No. (%)a | 0.17 | ||
Chemotherapy | 43 (61) | 32 (49) | |
Targeted therapy | 25 (35) | 3 (5) | |
Immunotherapy | 12 (17) | 21 (32) | |
Hormonal therapy | 4 (6) | 1 (2) | |
No therapy | 4 (6) | 3 (5) | |
Localized cancer treated with curative intention, No. (%) | 5 (7) | 7 (11) | 0.43 |